Leede Jones Gable Analyst Recommendations & Stock PicksView the latest stock recommendations issued by analysts at Leede Jones Gable. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Leede Jones Gable's equity research team. MarketBeat is not affiliated with or endorsed by Leede Jones Gable.Updated 8/7/2024 Brokerage RankingSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROITotal Ratings0 Last 12 MonthsBuy Ratings0 Last 12 MonthsSell Ratings0 Last 12 Months Country All Countries USA (NYSE & NASDAQ)USA (All Exchanges)CanadaUnited Kingdom Sector All Sectors AerospaceAuto/Tires/TrucksBasic MaterialsBusiness ServicesCommunication ServicesComputer and TechnologyConstructionConsumer CyclicalConsumer DefensiveConsumer DiscretionaryConsumer GoodsConsumer StaplesEnergyFinanceFinancial ServicesIndustrialsManufacturingMedicalMiscellaneousMulti-Sector ConglomeratesReal EstateRetail/WholesaleServicesTransportationUtilities Market Cap All MarketCaps Mega Cap (More Than $200B)Large Cap ($10B-$200B)Mid Cap ($2B-$10B)Small Cap ($300M-$2B)Micro Cap ($50M-$300M)Nano Cap (Under $50M) MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter Reporting Date Full History Latest Per Company Show All Ratings Strong Buy Buy Hold Sell Rating All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Price Target Change Action Any Change Raised 5%+ Raised 10%+ Raised 20%+ Lowered 5%+ Lowered 10%+ Lowered 20%+ Price Target Change Export CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetailsDRMedical FacilitiesC$17.108/7/2024 Boost Price TargetC$15.00 ➝ C$15.50Buy00.00%View details for Leede Jones Gable rating of Medical Facilities (TSE:DR) on 8/7/2024DRMedical FacilitiesC$17.105/9/2024D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeHold ➝ Buy00.00%View details for Leede Jones Gable rating of Medical Facilities (TSE:DR) on 5/9/2024TAUThesis GoldC$3.23-4.3%5/9/2024R. StewartSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for Leede Jones Gable rating of Thesis Gold (CVE:TAU) on 5/9/2024EXEExtendicareC$30.20-0.3%3/11/2024 Boost Price TargetC$7.00 ➝ C$8.50Buy00.00%View details for Leede Jones Gable rating of Extendicare (TSE:EXE) on 3/11/2024BRCBlackrock SilverC$1.19-0.8%2/13/2024R. StewartSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingSpeculative Buy00.00%View details for Leede Jones Gable rating of Blackrock Silver (CVE:BRC) on 2/13/2024EXEExtendicareC$30.20-0.3%11/13/2023D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeHold ➝ Buy00.00%View details for Leede Jones Gable rating of Extendicare (TSE:EXE) on 11/13/2023CRDLCardiol Therapeutics$1.31-1.5%9/19/2023D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingSpeculative Buy00.00%View details for Leede Jones Gable rating of Cardiol Therapeutics (NASDAQ:CRDL) on 9/19/2023ACDAccord FinancialC$1.50+0.7%8/16/2023G. McleishSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy00.00%View details for Leede Jones Gable rating of Accord Financial (TSE:ACD) on 8/16/2023PMNPromis Neurosciences$11.06-0.1%7/17/2023D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingSpeculative Buy00.00%View details for Leede Jones Gable rating of Promis Neurosciences (NASDAQ:PMN) on 7/17/2023SGDSnowline GoldC$15.93+3.0%4/20/2023G. McleishSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy00.00%View details for Leede Jones Gable rating of Snowline Gold (CVE:SGD) on 4/20/2023 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CPHCipher PharmaceuticalsC$18.11+0.8%3/17/2023D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy00.00%View details for Leede Jones Gable rating of Cipher Pharmaceuticals (TSE:CPH) on 3/17/2023THTheratechnologiesC$4.47-4.9%1/5/2023D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeHold ➝ Speculative Buy00.00%View details for Leede Jones Gable rating of Theratechnologies (TSE:TH) on 1/5/2023DRMedical FacilitiesC$17.1011/11/2022D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold00.00%View details for Leede Jones Gable rating of Medical Facilities (TSE:DR) on 11/11/2022ONCOncolytics BiotechC$14.90-1.3%3/4/2022D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingSpeculative Buy00.00%View details for Leede Jones Gable rating of Oncolytics Biotech (TSE:ONC) on 3/4/2022ONCYOncolytics Biotech$0.92-1.4%3/4/2022D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingSpeculative Buy00.00%View details for Leede Jones Gable rating of Oncolytics Biotech (NASDAQ:ONCY) on 3/4/2022ATBPFAntibe Therapeutics$0.2210/15/2021D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeSpeculative Buy ➝ Hold00.00%View details for Leede Jones Gable rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 10/15/2021SGDSnowline GoldC$15.93+3.0%10/7/2021G. McleishSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy00.00%View details for Leede Jones Gable rating of Snowline Gold (CVE:SGD) on 10/7/2021CRDLCardiol Therapeutics$1.31-1.5%8/24/2021D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingSpeculative Buy00.00%View details for Leede Jones Gable rating of Cardiol Therapeutics (NASDAQ:CRDL) on 8/24/2021CPHCipher PharmaceuticalsC$18.11+0.8%3/22/2021D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeSpeculative Buy ➝ Buy00.00%View details for Leede Jones Gable rating of Cipher Pharmaceuticals (TSE:CPH) on 3/22/2021KBLK-Bro LinenC$39.003/19/2021D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy00.00%View details for Leede Jones Gable rating of K-Bro Linen (TSE:KBL) on 3/19/2021DRMedical FacilitiesC$17.103/12/2021D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy00.00%View details for Leede Jones Gable rating of Medical Facilities (TSE:DR) on 3/12/2021PRNProfound MedicalC$9.88+8.3%3/4/2021D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy00.00%View details for Leede Jones Gable rating of Profound Medical (TSE:PRN) on 3/4/2021PROFProfound Medical$7.27+8.5%3/4/2021D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy00.00%View details for Leede Jones Gable rating of Profound Medical (NASDAQ:PROF) on 3/4/2021EXEExtendicareC$30.20-0.3%3/1/2021D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy00.00%View details for Leede Jones Gable rating of Extendicare (TSE:EXE) on 3/1/2021THTheratechnologiesC$4.47-4.9%2/26/2021D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeSpeculative Buy ➝ Hold00.00%View details for Leede Jones Gable rating of Theratechnologies (TSE:TH) on 2/26/2021ONCOncolytics BiotechC$14.90-1.3%2/24/2021D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingSpeculative Buy00.00%View details for Leede Jones Gable rating of Oncolytics Biotech (TSE:ONC) on 2/24/2021ONCYOncolytics Biotech$0.92-1.4%2/24/2021D. LoeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingSpeculative Buy00.00%View details for Leede Jones Gable rating of Oncolytics Biotech (NASDAQ:ONCY) on 2/24/2021 MarketBeat Community Rating for Leede Jones GableMarketBeat's community ratings are surveys of what our community members think about Leede Jones Gable and other research firms in the last 90 days. Vote "Outperform" if you believe Leede Jones Gable's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Leede Jones Gable's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days. Log in to vote on this brokerage. COMMUNITY RATINGS2.5out of 5 (last 90 days)2.5 of 5 stars OUTPERFORM VOTES 39 Believe will outperform S&P 500 UNDERPERFORM VOTES 39 Believe will underperform S&P 500 Best & Worst CallsBest Call0000.0%TSE:CPHReiterated Rating • Mar 17, 2023Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%NASDAQ:CRDLReiterated Rating • Aug 24, 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Similarly Rated FirmsNew Street ResearchSusquehannaClarkson CapitalTaglich BrothersWUWunderlichWall Street ZenCJS SecuritiesFox AdvisorsWedbushPhillip Securities Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
